Table 3.
Type D personality incidence data throughout the 208 weeks of follow-up.
| Generate tDp (n = 10) | No tDp (n = 56) | p-values | |
|---|---|---|---|
| Age (years) | 51.20 ± 4.2 | 51.51 ± 1.8 | 0.95 |
| Male:Female ratio | 1:4 | 19:9 | 0.004 |
| BMI | 27.63 ± 1.69 | 28.79 ± 0.71 | 0.51 |
| Educational level (%) | 0.37 | ||
| Primary incomplete | 1 (10.0) | 3 (5.36) | |
| Secondary | 7 (70.0) | 29 (51.79) | |
| Academic | 2 (20.0) | 24 (42.86) | |
| Marital status (%) | 0.97 | ||
| Single | 2 (20.0) | 10 (17.86) | |
| Married | 7 (70.0) | 41 (73.21) | |
| Divorced | 1 (10.0) | 5 (8.93) | |
| PASI (baseline) | 4.04 ± 1.68 | 4.16 ± 0.71 | 0.94 |
| PASI (week 208) | 1.00 ± 0.72 | 1.63 ± 0.30 | 0.42 |
| Baseline HADS-A >8 | 6 (60.0) | 14 (25.0) | 0.03 |
| Baseline HADS-D >8 | 5 (50) | 8 (14.29) | 0.01 |
| Baseline psoriasis treatment (%) | 0.92 | ||
| Topical | 1 (10.0) | 8 (14.29) | |
| Classical systemic drugs | 3 (30.0) | 17 (30.36) | |
| Biological drugs | 6 (60.0) | 31 (55.36) | |
| Final psoriasis treatment (%) | 0.14 | ||
| Topical | 3 (30.0) | 5 (9.09) | |
| Classical systemic drugs | 0 (0.0) | 4 (7.27) | |
| Biological drugs | 7 (70.0) | 46 (83.64) |
TDp, type D personality consists of a tendency to inhibit the expression of emotions or behavior to avoid negative reactions from others (Social Inhibition: SI), in combination with the stable tendency to experience Negative Affectivity (NA). Data are expressed as mean ± standard deviation and as number (percentage); BMI, Body Mass Index; PASI, Psoriasis Area and Severity Index; HADS, the Hospital Anxiety and Depression Scale-Anxiety (HADS-A) and Depression (HADS-D); p-values refer to the comparison of patients who develop type D and those who do not.